PMID- 36369970
OWN - NLM
STAT- MEDLINE
DCOM- 20221223
LR  - 20221223
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 47
IP  - 12
DP  - 2022 Dec
TI  - Central nervous system adverse events of ceftazidime/avibactam: A retrospective 
      study using Food and Drug Administration Adverse Event Reporting System.
PG  - 2369-2372
LID - 10.1111/jcpt.13796 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Many antibiotics are well known for being associated 
      with adverse events (AEs) of central nervous system, ceftazidime/avibactam 
      (CAZ/AVI) is a novel beta-lactam/beta-lactamase inhibitor combinations. In this 
      commentary, we analyzed reports of nervous system disorders associated with 
      CAZ/AVI, meropenem, imipenem, ceftazidime, ceftriaxone, and cefepime in the Food 
      and Drug Administration (FDA) Adverse Event Reporting System database from 
      January 2015 to March 2022. COMMENT: The reporting odds ratios (RORs) method was 
      used to detect the safety signals. Up to 15.62% of CAZ/AVI AEs exhibit nervous 
      system disorders associated with CAZ/AVI. A nervous system disorder signal was 
      detected for CAZ/AVI compared with meropenem, ceftazidime, and ceftriaxone. 
      Compared with meropenem, imipenem, ceftazidime, and ceftriaxone, encephalopathy, 
      myoclonus, reported with CAZ/AVI exhibited significant RORs. WHAT IS NEW AND 
      CONCLUSION: This study found that CAZ/AVI showed a relatively stronger sign 
      nervous system disorder than meropenem, ceftazidime, and ceftriaxone in the real 
      world. The poor clinical outcome of these events should attract clinical 
      attention, especially for patients with older than 65 years old and long 
      treatment courses.
CI  - (c) 2022 John Wiley & Sons Ltd.
FAU - Guo, Xiaolong
AU  - Guo X
AD  - Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, 
      Beijing, China.
AD  - Beijing Institute of Clinical Pharmacy, Beijing, China.
AD  - School of Pharmaceutical Sciences, Capital Medical University, Beijing, China.
AD  - Department of Pharmacy, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Guo, Mingxing
AU  - Guo M
AD  - Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, 
      Beijing, China.
FAU - Li, Jiyang
AU  - Li J
AD  - Department of Pharmacy, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Cui, Xiangli
AU  - Cui X
AUID- ORCID: 0000-0002-2992-5205
AD  - Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, 
      Beijing, China.
AD  - Beijing Institute of Clinical Pharmacy, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20221112
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 9M416Z9QNR (Ceftazidime)
RN  - FV9J3JU8B1 (Meropenem)
RN  - 7352665165 (avibactam)
RN  - 75J73V1629 (Ceftriaxone)
RN  - 0 (Anti-Bacterial Agents)
RN  - 71OTZ9ZE0A (Imipenem)
RN  - 0 (Drug Combinations)
SB  - IM
MH  - United States
MH  - Humans
MH  - Aged
MH  - *Ceftazidime/adverse effects
MH  - Meropenem/therapeutic use
MH  - Retrospective Studies
MH  - *Ceftriaxone
MH  - United States Food and Drug Administration
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Imipenem
MH  - Drug Combinations
MH  - Central Nervous System
MH  - Microbial Sensitivity Tests
OTO - NOTNLM
OT  - FAERS
OT  - ceftazidime/avibactam
OT  - central nervous system
OT  - signal detection
EDAT- 2022/11/13 06:00
MHDA- 2022/12/24 06:00
CRDT- 2022/11/12 04:12
PHST- 2022/10/10 00:00 [revised]
PHST- 2022/08/02 00:00 [received]
PHST- 2022/10/18 00:00 [accepted]
PHST- 2022/11/13 06:00 [pubmed]
PHST- 2022/12/24 06:00 [medline]
PHST- 2022/11/12 04:12 [entrez]
AID - 10.1111/jcpt.13796 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2022 Dec;47(12):2369-2372. doi: 10.1111/jcpt.13796. Epub 2022 
      Nov 12.